Safety and tolerability of enteric-coated mycophenolate sodium in combination with steroids and two regimen of Neoral®, in de novo kidney transplant recipients:: 6 months interim results.: A randomized, multicentre, open, prospective controlled study.

被引：0
|
作者：
Rostaing, L
Mourad, G
Legendre, C
机构：
[1] Hop Rangueil, Toulouse, France
[2] Hop Lapeyronie, Montpellier, France
[3] Hop St Louis, Paris, France
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2004年 / 4卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
222
引用
收藏
页码：219 / 219
页数：1
相关论文
共 50 条
  • [1] SAFETY AND TOLERABILITY OF ENTERIC COATED MYCOPHENOLATE SODIUM IN COMBINATION WITH NEORAL AND STEROIDS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: 12 MONTHS ANALYSIS OF A PROSPECTIVE TRIAL
    Rostaing, Lionel
    Legendre, C. H.
    Cohen, D.
    Budde, K.
    Zeier, M.
    Kirchherr, B.
    NEPHROLOGY, 2005, 10 : A215 - A215
  • [2] Tolerability of enteric coated mycophenolate sodium (EC-MPS) in combination with neoral and steroids in de novo kidney transplant recipients: A 12 months prospective trial.
    Legendre, CH
    Rostaing, L
    Kirchherr, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 464 - 465
  • [3] Sustainable tolerability effects of myfortic® in combination with Neoral® and steroids at 12 months, in de novo kidney transplantation:: A randomized, multicentre, open, prospective controlled study.
    Rostaing, L
    Mourad, G
    Legendre, C
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 190 - 190
  • [4] Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in de Novo Kidney Transplant Recipients in China: A Prospective Cohort Study
    Xie, Wenqing
    Peng, Wenhan
    He, Zhechi
    Lv, Junhao
    Lei, Wenhua
    Wang, Rending
    Huang, Hongfeng
    Wu, Jianyong
    Chen, Jianghua
    TRANSPLANTATION, 2022, 106 (09) : S156 - S156
  • [5] Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: Results of a 12-month mulitcentre, open-label, prospective study.
    Vitko, S
    Vogt, B
    Antoniadis, A
    Klinger, M
    Kirchher, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 191 - 192
  • [6] Enteric-coated mycophenolate sodium in combination with optimized Neoral dosing, basiliximab, and steroids results in good efficacy and renal function in renal transplant recipients in the first 6 months.
    Cibrik, DM
    Jensik, S
    Meier-Kriesche, HU
    Bresnahan, B
    Lieberman, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 218 - 218
  • [7] The efficacy and safety of intensified enteric-coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study
    Zhang, H.
    Liu, L.
    Li, J.
    Fu, Q.
    Wan, J.
    Deng, R.
    Wang, H.
    Liao, J.
    Deng, W.
    Deng, S.
    Chen, L.
    Wang, C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 : 22 - 30
  • [8] Efficacy and safety of enteric-coated mycophenolate sodium, cyclosporiine and steroids in De novo pediatric renal transplant patients:: 12-months results of a multicenter study
    Niaudet, Patrick
    Loirat, Chantal
    Tsimaratos, Michel
    Dehennault, Maud
    Quere, Stephane
    Lemay, Djamila
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 372 - 372
  • [9] Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: Results of a 12-month multicenter, open-label, prospective study
    Vogt, B.
    Antoniadis, A.
    Klinger, M.
    Vitko, S.
    TRANSPLANTATION PROCEEDINGS, 2006, 38 (05) : 1301 - 1306
  • [10] Enteric-coated mycophenolate sodium (EC-MPS) is comparable to mycophenolate mofetil in de novo heart transplant patients. Twelve months efficacy and safety results.
    Kobashigawa, JA
    Gerosa, G
    Caforio, A
    Renlund, DG
    Ross, H
    Yonan, N
    Hummel, M
    Segovia, J
    Almenar, L
    Brambilla, R
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 244 - 244
12345